At JDRF, we know that when it comes to fighting against type 1 diabetes (T1D), there is strength in numbers.
Using your voice to fight against type 1 diabetes
Advocating for insulin pumps in Manitoba
JDRF’s message to the government was straightforward and simple: Manitobans with type 1 diabetes at all ages need access to insulin pumps.
#AccessForAll in the age of COVID-19
As COVID-19 continues to dominate global headlines, the journey to #AccessForAll remains.
Tannis M. Richardson: T1D Champion Gives Back to the Community
Giving back to others has been a way of life since Tannis was a young girl growing up in Winnipeg. Her parents were always community-minded, with hersurgeon father establishing the first collective medical facility, the Winnipeg Clinic, and her mother lending support to various organizations.
Advancing cell replacement therapies to treat more people with type 1 diabetes
Dr. Pepper is a promising young Canadian scientist and a new assistant professor in the Department of Surgery at the University of Alberta.
I have type 1 diabetes (T1D) and am worried I’ll have to go into the hospital during the COVID-19 outbreak. How can I prepare?
Below are a few tips to help you better cope in case a hospital visit is required.
Type 1 diabetes (T1D) and COVID-19: Frequently Asked Questions
JDRF Canada consulted a panel of Canadian endocrinologists to provide answers to some of your most frequently asked questions.
A letter to the T1D community from JDRF President and CEO Dave Prowten
I have been blown away by the strength, resilience and generosity demonstrated by you, our JDRF family. I am reminded of how privileged we are to have your continued support.
Severe lows? Spray it in the nose! New Nasal Glucagon for severe hypoglycemia available in Canada!
March 24, 2020 Sponsored Content by Ei Lilly Canada Eli Lilly Canada is pleased to announce the approval and availability of BaqsimiTM, a new rescue treatment for severe hypoglycemia, demonstrating […]
Novel dual-hormone artificial pancreas offers hope for better management of T1D
Drs. Ahmad Haidar, Laurent Legault, Michael Tsoukas and Jean-Franҫois Yale are a team of JDRF-funded researchers at McGill University (Montreal) who are the first to test the addition of pramlintide (a synthetic form of amylin, which is a hormone co-secreted with insulin by the healthy pancreas) to an artificial pancreas system – a combined treatment they hypothesize would help patients achieve optimal glucose control during the day.
Meet the 2020 Manitoba Lobby Day Delegates!
We’re so happy to share our 8 finalists with you – meet our 2020 Manitoba Lobby Day Delegates!
A Look into the 2020 Pre-Budget Consultations
JDRF President and CEO Dave Prowten testified recently in front of the Standing Committee on Finance as part of their 2020 Pre-Budget Consultations. Also appearing on JDRF’s behalf was Angie Sullivan, parent of a child with type 1 diabetes (T1D).
